Zymeworks (ZYME) Stock Price, Quote, News & History | Benzinga

SPY767.46+0.55%QQQ720.06+1.45%BTC/USD—DIA518.78−0.06%GLD380.03−0.52%TLT79.71−0.42%

Zymeworks Inc (ZYME) Stock Price, Quote, News & History

ZYMENASDAQ

Trade with Public

Trade with Public

$25.03

N/A

Last update: Oct 16, 4:00 PM

$25.03

N/A

OverviewNews Earnings Forecast Events Price Targets Financials Sentiment Ownership Compare Options Stock Report

Key Statistics

Open

$25.43

Close

-

Volume / Avg.

81.36K / 767.59K

Day Range

$25.06 - $25.70

52 Wk Range

16.00 - 31.34

Market Cap

$1.80B

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

49

Short Interest

11.15%

Days to Cover

5.55

Recent Zymeworks Inc. News

Zymeworks Updates Annual Financial Targets After Finalizing Theravance Biopharma Deal

Zymeworks completes its Theravance Biopharma acquisition, boosts 2026 revenue guidance, and gains recurring revenue from YUPELRI sales.

Vandana Singh

Abercrombie & Fitch Posts Upbeat Q2 Results, Joins Semtech, Summit Therapeutics And Other Big Stocks Moving Higher On Wednesday

U.S. stocks mixed, Nasdaq up 0.1%. Abercrombie & Fitch shares surge 31.6% after beating earnings and raising forecasts. Other top gainers include Kanzhun, Capricor Therapeutics, Semtech Corp, and more.

Avi Kapoor

MongoDB To Rally Around 14%? Here Are 10 Top Analyst Forecasts For Wednesday

Top analysts changed outlook on top names: Piper raised $INTU price target, Ascendiant raised $QUBT target, BTIG cut $DKS target, HC raised $ZYME target, Needham increased $JAZZ target, Bernstein cut $MSTR target, Barclays raised $MDB target, UBS raised $SMTC target.

Avi Kapoor

Jazz Pharmaceuticals Wins FDA Approval For Two Advanced Gastric Cancer Regimens

FDA approves Jazz Pharmaceuticals' Ziihera combinations for first-line treatment of HER2-positive gastroesophageal adenocarcinoma.

Vandana Singh

Zymeworks Targets Long-Term Cash Generation Through Theravance Acquisition

Zymeworks will acquire Theravance Biopharma for $929 million, adding YUPELRI cash flows and expanding its portfolio.

Vandana Singh

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-119.34M

Investing Cash Flow (TTM)

92.77M

Financing Cash Flow (TTM)

107.57M

Free Cash Flow (TTM)

-120.68M

Capital Expenditure (TTM)

-1.35M

Net Change in Cash (TTM)

81.01M

Analyst Trends and Forecast

1

Jul

6

Aug

3

Sep

1

Oct

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

4.0

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$1.54B

PE Ratio (TTM)

-

PE Ratio (FWD)

18.98

PEG Ratio (TTM)

-

PS Ratio (TTM)

50.35

PB Ratio (TTM)

22.35

Earnings Yield % (TTM)

-8.07%

Earnings Yield % (FWD)

5.27%

EV / EBITDA (TTM)

-

Price / EBITDA (TTM)

-

Price / Free Cash Flow (TTM)

-

Book Value / Share

$1.12

Company Debt

Total Debt

-

LT Debt

-

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-

Total Cash

$179.41M

Debt to Equity

0.20

Issuance of Debt (TTM)

-

Repayment of Debt (TTM)

-